Evidence map›Paper›PMID 35743704›Full record

ArticleJournal of personalized medicine2022

Targeted RNAseq Improves Clinical Diagnosis of Very Early-Onset Pediatric Immune Dysregulation.

Kiera Berger, Dalia Arafat, Shanmuganathan Chandrakasan, Scott B Snapper, Greg Gibson

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. RNA Sequencing in Disease Diagnosis.Annual review of genomics and human genetics · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kiera BergerSchool of Biological Sciences, Georgia Institute of Technology, Atlanta, GA 30332, USA.ORCID 0000-0002-3995-7892
Dalia ArafatSchool of Biological Sciences, Georgia Institute of Technology, Atlanta, GA 30332, USA.ORCID 0000-0002-5418-1738
Shanmuganathan ChandrakasanDivision of Bone Marrow Transplant, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA 30322, USA.
Scott B SnapperDivision of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA 02115, USA.
Greg GibsonSchool of Biological Sciences, Georgia Institute of Technology, Atlanta, GA 30332, USA.ORCID 0000-0002-5352-5877

Funding

New computational, transcriptional, and genome editing approaches to the biology of inflammatory bowel diseaseR01DK119991 · NIDDK · GEORGIA INSTITUTE OF TECHNOLOGY · PI GIBSON, GREGORY C · 2018 to 2021
$692k
NIDDK NIH HHS 1-R01-DK119991NIDDK NIH HHS R01 DK119991
6 · The paper itself

Abstract

Despite increased use of whole exome sequencing (WES) for the clinical analysis of rare disease, overall diagnostic yield for most disorders hovers around 30%. Previous studies of mRNA have succeeded in increasing diagnoses for clearly defined disorders of monogenic inheritance. We asked if targeted RNA sequencing could provide similar benefits for primary immunodeficiencies (PIDs) and very early-onset inflammatory bowel disease (VEOIBD), both of which are difficult to diagnose due to high heterogeneity and variable severity. We performed targeted RNA sequencing of a panel of 260 immune-related genes for a cohort of 13 patients (seven suspected PID cases and six VEOIBD) and analyzed variants, splicing, and exon usage. Exonic variants were identified in seven cases, some of which had been previously prioritized by exome sequencing. For four cases, allele specific expression or lack thereof provided additional insights into possible disease mechanisms. In addition, we identified five instances of aberrant splicing associated with four variants. Three of these variants had been previously classified as benign in ClinVar based on population frequency. Digenic or oligogenic inheritance is suggested for at least two patients. In addition to validating the use of targeted RNA sequencing, our results show that rare disease research will benefit from incorporating contributing genetic factors into the diagnostic approach.

Indexed as

primary immune deficienciesrare diseaseRNAseqsplicingvery early-onset inflammatory bowel disease

Identifiers

PMID35743704
PMCPMC9224647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.